Treating anemia of chronic kidney disease in the primary care setting: Cardiovascular outcomes and management recommendations

Osteopathic Medicine and Primary Care

Volumn 1, Issue , 2007, Pages

  Schmidt, Rebecca J ^a   Dalton, Cheryl L ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37449015042     PISSN: None     EISSN: 17504732     Source Type: Journal    
DOI: 10.1186/1750-4732-1-14     Document Type: Review

References (79)

1. Drueke TB Eckardt KU Frei U Jacobs C Kokot F McMahon LP Schaefer RM: Does early anemia correction prevent complications of chronic renal failure? Clin Nephrol 1999, 51:1-11. 9988140
2. Nurko S: Anemia in chronic kCdney disease: causes, diagnosis, treatment. Cleve Clin J Med, 2006, 73:289-297. 16548452
3. McClellan W Aronoff SL Bolton WK Hood S Lorber DL Tang KL Tse TF Wasserman B Leiserowitz M: The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004, 20:1501-1510. 10.1185/ 030079904X2763 15383200
4. Hsu CY McCulloch CE Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002, 13:504-510. 10.1097/01.ASN.0000034200.82278.DC 11805181
5. Walker AM Schneider G Yeaw J Nordstrom B Robbins S Pettitt D: Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol 2006, 17:2293-2298. 10.1681/ASN.2005020183 16837634
6. Levin A Singer J Thompson CR Ross H Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996, 27:347-354. 8604703
7. Levin A Thompson CR Ethier J Carlisle EJ Tobe S Mendelssohn D Burgess E Jindal K Barrett B Singer J Djurdjev O: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999, 34:125-134. 10401026
8. Khan SS Kazmi WH Abichandani R Tighiouart H Pereira BJ Kausz AT: Health care utilization among patients with chronic kidney disease. Kidney Int 2002, 62:229-236. 10.1046/j.1523-1755.2002.00432.x 12081582
9. Fink J Blahut S Reddy M Light P: Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001, 37:348-355. 11157377
10. Revicki DA Brown RE Feeny DH Henry D Teehan BP Rudnick MR Benz RL: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995, 25:548-554. 7702049
11. Clyne N Jogestrand T: Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992, 60:390-396. 1584314
12. Lim VS DeGowin RL Zavala D Kirchner PT Abels R Perry P Fangman J: Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989, 110:108-114. 2909202
13. Besarab A Soman S: Anemia management iL chronic heart failure: lessons learnt from chronic kidney disease. Kidney Blood Press Res 2005, 28:363-371. 10.1159/000090191 16534232
14. Johnson CA Levey AS Coresh J Levin A Lau J Eknoyan G: Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician 2004, 70:869-876. 15368726
15. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-266. 10.1053/ajkd.2002.32799 11904577
16. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006, 47:S11-145. 10.1053/j.ajkd.2006.03.010 16678659
17. Fox CH Brooks A Zayas LE McClellan W Murray B: Primary care physicians' knowledge and practice patterns in the treatment of chronic kidney disease: An Upstate New York Practice-based Research Network (UNYNET) study. J Am Board Fam Med 2006, 19:54-61. 16492006
18. Arora P Obrador GT Ruthazer R Kausz AT Meyer KB Jenuleson CS Pereira BJ: Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol 1999, 10:1281-1286. 10361866
19. Zillich AJ Saseen JJ Dehart RM Dumo P Grabe DW Gilmartin C Hachey DM Hudson JQ Pruchnicki MC Joy MS: Caring for patients with chronic kidney disease: A joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy 2005, 25:123-143. 10.1592/phco.25.1.123.55628 15767229
20. Arora P Mustafa RA Karam J Khalil P Wilding G Ranjan R Lohr J: Care of elderly patients with chronic kidney disease. Int Urol Nephrol 2006, 38:363-370. 10.1007/s11255-006-0046-x 16868713
21. National Kidney Foundation - Kidney Early Evaluation Program: KEEP Annual Data Report 2006. Am J Kidney Dis 2007, 49:S1-S160.
22. Kiberd B: The chronic kidney diSease epidemic: stepping back and looking forward. J Am Soc Nephrol 2006, 17:2967-2973. 10.1681/ASN.2006020123 17035615
23. Gilbertson DT Liu J Xue JL Louis TA Solid CA Ebben JP Collins AJ: Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005, 16:3736-3741. 10.1681/ASN.2005010112 16267160
24. St Peter WL Schoolwerth AC McGowan T McClellan WM: Chronic kidney disease: Issues and establishing programs and clinics for improved patient outcomes. Am J Kidney Dis 2003, 41:903-924. 10.1016/ S0272-6386(03)00188-4 12722025
25. Shah N Dahl NV Kapoian T Sherman RA Walker JA. The nephrologist as a primary care provider for the hemodialysis patient. Int Urol Nephrol 2005, 37:113-117. 10.1007/s11255-004-0875-4 16132772
26. Hunsicker LG: The consequences and costs of chronic kidney disease before ESRD. J Am Soc Nephrol 2004, 15:1363-1364. 10.1097/ 01.ASN.0000126069.68755.99 15100382
27. Collins AJ Li S Gilbertson DT Liu J Chen SC Herzog CA: Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003, S24-31. 10.1046/j.1523-1755.64.s87.5.x 14531770
28. Smith DH Gullion CM Nichols G Keith DS Brown JB: Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004, 15:1300-1306. 10.1097/ 01.ASN.0000125670.64996.BB 15100370
29. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007, 50:471-530. 10.1053/j.ajkd.2007.06.008 17720528
30. Boulware LE Troll MU Jaar BG Myers DI Powe NR: Identification and referral of patients with progressive CKD: A national study. Am J Kidney Dis 2006, 48:192-204. 10.1053/j.ajkd.2006.04.073 16860184
31. Coresh J Astor BC Greene T Eknoyan G Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1-12. 10.1053/ajkd.2003.50007 12500213
32. Hsu CY Vittinghoff E Lin F Shlipak MG: The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004, 141:95-101. 15262664
33. United States Renal Data System: Atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2003.
34. United States Renal Data System: Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004.
35. United States Renal Data System: Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
36. Schoolwerth AC Engelgau MM Hostetter TH Rufo KH Chianchiano D McClellan WM Warnock DG ViniAor F: Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis 2006, 3:A57. 1563984 16539798
37. Astor BC Muntner P Levin A Eustace JA Coresh J: Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002, 162:1401-1408. 10.1001/archinte.162.12.1401 12076240
38. Eckardt KU Mollmann M Neumann R Brunkhorst R Burger HU Lonnemann G Scholz H Keusch G Buchholz B Frei U: Erythropoietin in polycystic kidneys. J Clin Invest 1989, 84:1160-1166. 329773 2794053
39. Pavlovic-Kentera V Clemons GK Djukanovic L Biljanovic-Paunovic L: Erythropoietin and anemia in chronic renal failure. Exp Hematol 1987, 15:785-789. 3609182
40. Deicher R Horl WH: Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2003, 12:139-143. 10.1097/00041552-200303000-00003 12589173
41. Donnelly S: Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 2001, 38:415-425. 11479173
42. Hillege HL van Gilst WH van Veldhuisen DJ Navis G Grobbee DE de Graeff PA de Zeeuw D: Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003, 24:412-420. 10.1016/ S0195-668X(02)00526-2 12633543
43. Avorn J Bohn RL Levy E Levin R Owen WF Jr Winkelmayer WC Glynn RJ: Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med 2002, 162:2002-2006. 10.1001/ archinte.162.17.2002 12230424
44. Felker GM Adams KF Jr Gattis WA O'Connor CM: Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004, 44:959-966. 10.1016/j.jacc.2004.05.070 15337204
45. Silverberg DS Wexler D Blum M Keren G Sheps D Leibovitch E Brosh D Laniado S Schwartz D Yachnin T: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000, 35:1737-1744. 10.1016/S0735-1097(00)00613-6 10841219
46. Silverberg DS Wexler D Blum M Tchebiner JZ Sheps D Keren G Schwartz D Baruch R Yachnin T Shaked M: The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003, 18:141-146. 10.1093/ndt/ 18.1.141 12480972
47. Silverberg DS Wexler D Sheps D Blum M Keren G Baruch R Schwartz D Yachnin T Steinbruch S Shapira I: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 2001, 37:1775-1780. 10.1016/S0735-1097(01)01248-7 11401110
48. Go AS Yang J Ackerson LM Lepper K Robbins S Massie BM Shlipak MG: Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006, 113:2713-2723. 10.1161/CIRCULATIONAHA.105.577577 16754803
49. Muntner P He J Astor BC Folsom AR Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005, 16:529-538. 10.1681/ASN.2004080656 15625072
50. Jurkovitz CT Abramson JL Vaccarino LV Weintraub WS McClellan WM: Association of high serum creatinine and anemia increases the risk of coronary events: Results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003, 14:2919-2925. 10.1097/01.ASN.0000092138.65211.71 14569102
51. Kovesdy CP Trivedi BK Kalantar-Zadeh K Anderson JE: Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006, 69:560-564. 10.1038/sj.ki.5000105 16395253
52. Mohanram A Zhang Z Shahinfar S Keane WF Brenner BM Toto RD: Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004, 66:1131-1138. 10.1111/ j.1523-1755.2004.00863.x 15327408
53. McCullough PA Lepor NE: Piecing togTther the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 2005, 6(Suppl 3):S4-12. 16340933
54. Ayus JC Go AS Valderrabano F Verde E de Vinuesa SG Achinger SG Lorenzo V Arieff AI Luno J: Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int 2005, 68:788-795. 10.1111/ j.1523-1755.2005.00458.x 16014057
55. Dean BB Dylan M Gano A Jr Knight K Ofman JJ Levine BS: Erythropoiesis-stimulating protein therapy and the decline of renal function: A retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005, 21:981-987. 10.1185/030079905X49644 16004664
56. Levin A Djurdjev O Thompson C Barrett B Ethier J Carlisle E Barre P Magner P Muirhead N Tobe S: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005, 46:799-811. 10.1053/j.ajkd.2005.08.007 16253719
57. Roger SD McMahon LP Clarkson A Disney A Harris D Hawley C Healy H Kerr P Lynn K Parnham A: Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 2004, 15:148-156. 10.1097/01.ASN.0000102471.89084.8B 14694167
58. Gouva C Nikolopoulos P Ioannidis JP Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 2004, 66:753-760. 10.1111/ j.1523-1755.2004.00797.x 15253730
59. Jungers P Choukroun G Oualim Z Robino C Nguyen AT Man NK: Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001, 16:307-312. 10.1093/ndt/16.2.307 11158405
60. Singh AK Szczech L Tang KL Barnhart H Sapp S Wolfson M Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098. 10.1056/NEJMoa065485 17108343
61. Drueke TB Locatelli F Clyne N Eckardt KU Macdougall IC Tsakiris D Burger HU Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084. 10.1056/NEJMoa062276 17108342
62. Locatelli F Del Vecchio L Tozzoni P: Anemia and cardiovascular risk: the lesson of the CREATE trial. J Am Soc Nephrol 2006, 17:S262-S266. 10.1681/ ASN.2006080924 17130272
63. Besarab A Bolton WK Browne JK Egrie JC Nissenson AR Okamoto DM Schwab SJ Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590. 10.1056/NEJM199808273390903 9718377
64. Eschbach JW Abdulhadi MH Browne JK Delano BG Downing MR Egrie JC Evans RW Friedman EA Graber SE Haley NR: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989, 111:992-1000. 2688507
65. Roth D Smith RD Schulman G Steinman TI Hatch FE Rudnick MR Sloand JA Freedman BI Williams WW Jr Shadur CA: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994, 24:777-784. 7977319
66. Rossert J Levin A Roger SD Horl WH Fouqueray B Gassmann-Mayer C Frei D McClellan WM: Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006, 47:738-750. 10.1053/j.ajkd.2006.02.170 16632012
67. Cody J Daly C Campbell M Donaldson C Khan I Rabindranath K Vale L Wallace S Macleod A: Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005, CD003266. 16034896
68. Aranesp(R)[US prescribing information]. Thousand Oaks, CA: Amgen, Inc; 2007.
69. Epogen(R) [US prescribing information]. Thousand Oaks, CA: Amgen, Inc; 2007.
70. Thomas MC Cooper ME Rossing K Parving HH: Anaemia in diabetes: Is there a rationale to TREAT? Diabetologia 2006, 49:1151-1157. 10.1007/ s00125-006-0215-6 16586069
71. Pfeffer MA: An ongoing study of anemia correction in chronic kidney disease. N Engl J Med 2007, 356:959-961. 10.1056/NEJMc066568 17329707
72. Public Health Advisory: Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp) http://www.fda.gov/cder/drug/ advisory/RHE.htm
73. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa) http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm
74. Rossert J Froissart M Jacquot C: Anemia management and chronic renal failure progression. Kidney Int Suppl 2005, S76-81. 10.1111/ j.1523-1755.2005.09914.x 16336582
75. Nissenson AR: Epoetin and cognitive function. Am J Kidney Dis 1992, 20:21-24. 1626553
76. Moreno F Sanz-Guajardo D Lopez-Gomez JM Jofre R Valderrabano F: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000, 11:335-342. 10665941
77. Mancini DM Katz SD Lang CC LaManca J Hudaihed A Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003, 107:294-299. 10.1161/ 01.CIR.0000044914.42696.6A 12538431
78. Silverberg DS Wexler D Blum M Iaina A Sheps D Keren G Scherhag A Schwartz D: Effects of treatment with epoetin beta on outcomes in patients with anaemia and chronic heart failure. Kidney Blood Press Res 2005, 28:41-47. 10.1159/000081621 15489560
79. Kuriyama S Tomonari H Yoshida H Hashimoto T Kawaguchi Y Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997, 77:176-185. 9346384